NBP

NovaBridge Biosciences is a clinical-stage biopharmaceutical company with a pipeline of four drug candidates, having recently divested its Greater China portfolio including uliledlimab, lemzoparlimab, and givastomig to focus on ex-China development. The company has expanded into ophthalmology through the establishment of Visara and acquisition of Bridge Health, with VIS-101 representing a key development asset in this emerging therapeutic area. NovaBridge currently generates revenue primarily through licensing and collaboration arrangements, including past agreements with AbbVie, while working toward future commercialization of its clinical-stage candidates.

Pipeline

Catalyst Calendar